Core Insights - Gilead Sciences has exercised its option to exclusively license Assembly Biosciences' herpes simplex virus helicase-primase inhibitor programs, marking the first advancement under their collaboration [1][2] Licensing Agreement - Gilead entered a 12-year partnership with Assembly Biosciences in 2023 to develop novel antiviral therapies, with Assembly Bio receiving a $35 million payment upon Gilead's exercise of its option [2] - Gilead will obtain exclusive rights to ABI-5366 and ABI-1179, taking full responsibility for their clinical development and commercialization [2] Financial Milestones - Assembly Biosciences is eligible for up to $330 million in regulatory and commercial milestones, along with tiered royalties on net sales [3][7] Product Development - ABI-1179 and ABI-5366 are long-acting helicase-primase inhibitors showing strong antiviral activity and significant reduction in virus-positive lesions in interim data from early-stage studies [8][9] - Over four million people in the U.S. and some European countries suffer from recurrent genital herpes, indicating a substantial market opportunity for these new therapies [9][10] Market Context - No new HSV therapies have been approved in the U.S. or Europe in over 25 years, highlighting the potential impact of ABI-5366 and ABI-1179 if successfully developed [9][10] Gilead's HIV Portfolio - Gilead has a leading HIV franchise, with products like Biktarvy and Descovy driving top-line growth [11] - The recent FDA approval of lenacapavir for HIV prevention enhances Gilead's portfolio, especially as Truvada faces generic competition [12]

Core Insights - Cocrystal Pharma, Inc. has completed a private placement of units, raising $1.03 million through the sale of 743,024 shares at $1.39 per share, along with unregistered warrants for an additional potential $1.8 million if fully exercised [1][3] Group 1: Investment Details - The private placement includes unregistered warrants to purchase up to 1,486,048 shares at an exercise price of $1.24 per share, which are exercisable upon issuance and will expire in 27 months [1][3] - The total potential proceeds from the warrants, if fully exercised, could amount to approximately $1.83 million [3] Group 2: Key Investors - The investors in this private placement include Cocrystal Directors Phillip Frost, Fred Hassan, Richard Pfenniger, and co-CEO and CFO James Martin, indicating strong confidence from the company's leadership [2] Group 3: Company Mission and Use of Proceeds - The company aims to utilize the net proceeds from this offering to support its clinical development programs, working capital, and general corporate purposes, reinforcing its commitment to advancing antiviral therapies [3][6] - Cocrystal Pharma focuses on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis, employing unique structure-based technologies [6]